Teleflex (NYSE:TFX) Bolsa

TELEFLEX INC

Teleflex

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.

Teleflex Inc

Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and lowers the price target from $140 to $137.

News

Price Target

Analyst Ratings

Truist Securities Maintains Hold on Teleflex, Lowers Price Target to $137

Morgan Stanley analyst Patrick Wood maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Overweight and lowers the price target from $191 to $173.

Morgan Stanley Maintains Overweight on Teleflex, Lowers Price Target to $173

RBC Capital analyst Shagun Singh maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Sector Perform and lowers the price target from $150 to $145.

RBC Capital Maintains Sector Perform on Teleflex, Lowers Price Target to $145

Wells Fargo analyst Larry Biegelsen maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Equal-Weight and lowers the price target from $146 to $137.

Wells Fargo Maintains Equal-Weight on Teleflex, Lowers Price Target to $137

WIIM

Teleflex shares are trading lower after the company reported Q1 financial results and cut its FY25 adjusted EPS guidance below estimates. Also, the company announced it expects an impact from tariffs.

Guidance

For 2025, Teleflex Says 'We expect an impact from tariffs of approximately $55 million in 2025, which will be recorded in cost of goods sold. We are currently evaluating mitigation strategies to reduce this exposure'

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) lowers FY2025 Adj EPS guidance from $13.95-$14.35 to $13.20-$13.60 vs $14.13 analyst estimate..

Teleflex Lowers FY2025 Adj EPS Guidance from $13.95-$14.35 to $13.20-$13.60 vs $14.13 Est

Earnings

Earnings Beats

Teleflex Q1 Adj. EPS $2.91 Beats $2.87 Estimate, Sales $700.70M Beat $699.32M Estimate

AAMI

AAPL

ABNB

ACCO

ADPT

AGCO

AGIO

ALHC

ALKS

ALNY

ALSN

AMGN

AMWL

AMZN

APLE

APTV

ARDX

ARVN

ASND

ASPS

ASUR

ATEC

ATEN

AXTI

BBAI

BIIB

BJRI

BLDR

BMRN

BOOM

BPMC

BRFH

CABO

CARR

CART

CERS

CMLS

COHN

COHU

COLM

COMM

COOK

CRAI

CTRE

CUBE

CWST

DBRG

DINO

DSGR

DUOL

DXCM

ECVT

ELME

Earnings Scheduled For May 1, 2025

The QuikClot Control+ Device was previously indicated for temporary control of class III and class IV internal organ space bleeding, severely bleeding surgical wounds, mild and moderate bleeding in cardiac surgical procedures, and bone surfaces following sternotomy.

Health Care

General

The FDA Has Granted 510(k) Clearance Of An Expansion To The Indications For Use Of Teleflex's QuikClot Control+ Hemostatic Device To Include All Grades Of Internal And External Bleeding

Truist Securities analyst Richard Newitter maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Hold and lowers the price target from $149 to $140.

Truist Securities Maintains Hold on Teleflex, Lowers Price Target to $140

Teleflex's (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) short percent of float has risen 116.84% since its last report. The company recently reported that it has 2.42 million shares sold short, which is 8.37% of all regular shares that are available for trading. Based on its trading volume, it would take traders 1.84 days to cover their short positions on average.
<h3>Why Short Interest Matters</h3>
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. <a href="https://www.benzinga.com/money/how-to-short-a-stock?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">Short selling</a> is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises.
Short interest is important to track because it can act as an indicator of market sentiment towards a particular stock. An increase in short interest can signal that investors have become more bearish, while a decrease in short interest can signal they have become more bullish.
See Also: <a href="https://www.benzinga.com/short-interest?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">List of the most shorted stocks</a>
<h3>Teleflex Short Interest Graph (3 Months)</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1743685231_0.png" alt="short_fig" />
As you can see from the chart above the percentage of shares that are sold short for Teleflex has grown since its last report. This does not mean that the stock is going to fall in the near-term but traders should be aware that more shares are being shorted.
<h3>Comparing Teleflex's Short Interest Against Its Peers</h3>
Peer comparison is a popular technique amongst analysts and investors for gauging how well a company is performing. A company's peer is another company that has similar characteristics to it, such as industry, size, age, and financial structure. You can find a company's peer group by reading its 10-K, proxy filing, or by doing your own similarity analysis.
According to <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>, Teleflex's peer group average for short interest as a percentage of float is 4.23%, which means the company has more short interest than most of its peers.
Did you know that increasing short interest can actually be bullish for a stock? <a href="https://www.benzinga.com/money/how-to-make-money-on-a-short-squeeze?adType=benzinga-insights&amp;ad=short-interest&amp;campaign=wallstreetadvantage">This post by Benzinga Money explains how you can profit from it.</a>
This article was generated by Benzinga's automated content engine and was reviewed by an editor.

Short Sellers

Short Ideas

Trading Ideas

Is the Market Bullish or Bearish on Teleflex?

Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) has been analyzed by 5 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Teleflex, revealing an average target of $153.2, a high estimate of $191.00, and a low estimate of $140.00. Observing a downward trend, the current average is 35.03% lower than the prior average price target of $235.80. 
<img src="https://www.benzinga.com/files/images/story/2025/1743616859_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of Teleflex by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Wood</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$191.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Lowers</td>
<td>Underperform</td>
<td>$140.00</td>
<td>$235.00</td>
</tr>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Lowers</td>
<td>Hold</td>
<td>$149.00</td>
<td>$200.00</td>
</tr>
<tr>
<td>Larry Biegelsen</td>
<td>Wells Fargo</td>
<td>Lowers</td>
<td>Equal-Weight</td>
<td>$146.00</td>
<td>$214.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$255.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Teleflex. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Teleflex compared to the broader market.</li>
<li>Price Targets: Analysts predict movements in price targets, offering estimates for Teleflex's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Teleflex's market standing. Stay informed and make data-driven decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/TFX/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Teleflex analyst ratings.</a>
<h2>Delving into Teleflex's Background</h2>
Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (24% of 2024 sales), interventional (19%), anesthesia (13%), surgical (15%), interventional urology (11%), original-equipment manufacturing (11%), and other (7%). Geographic exposure for the business is primarily in the US, which accounts for 60% of revenue, with international markets making up the remainder.
<h3>A Deep Dive into Teleflex's Financials</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3 months period, Teleflex showcased positive performance, achieving a revenue growth rate of 2.78% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: Teleflex's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of -17.18%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Teleflex's ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of -3.12%, the company may face hurdles in achieving optimal financial performance.
Return on Assets (ROA): Teleflex's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of -1.87%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Teleflex's debt-to-equity ratio is below the industry average at 0.41, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

5 Analysts Assess Teleflex: What You Need To Know

Citizens Capital Markets analyst David Turkaly reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Market Perform to Market Perform.

Reiteration

Citizens Capital Markets Reiterates Market Perform on Teleflexto Market Perform

Teleflex Receives FDA 510(k) Clearance Of The AC3 Range Intra-Aortic Balloon Pump (IABP)

<ul>
<li>The Ringer&#x2122; PBC study is a limited prospective, multi-center, single-arm IDE study, undertaken at four sites in the United States investigating the Ringer&#x2122;&nbsp;PBC for the management of emergent coronary perforations that develop during percutaneous coronary intervention (PCI) procedures. The study enrolled 30 participants, and analysis was performed based upon intention-to-treat. The primary efficacy endpoint required successful Ringer&#x2122; PBC delivery and inflation at the perforation site, control of extravasation (defined as residual Ellis grade 0 or 1), and preservation of antegrade coronary flow (Thrombolysis in Myocardial Infarction [TIMI] grade 2 or 3).</li>
<li>Of 30 participants enrolled, the primary efficacy endpoint was observed in 22 participants (73.3%), with successful Ringer&#x2122;&nbsp;PBC delivery in 26 participants (86.7%). Among those participants with successful delivery, control of extravasation with perfusion was achieved in 22 participants (84.6%). Twelve participants were treated with a covered stent following perforation management with the Ringer&#x2122;&nbsp;PBC. One participant required emergency surgery for complications of pericardiocentesis, and three participants died despite control of extravasation from the index perforation.</li>
</ul>

Teleflex Announced That The Preliminary Results From Its Ringer PBC IDE Study Were Reported In A Featured Presentation At The CTO Plus Conference

Needham analyst Mike Matson reiterates Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Hold to Hold.

Needham Reiterates Hold on Teleflexto Hold

DoorDash Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DASH#NASDAQ">DASH</a>) shares are trading higher Monday amid the company joining the <a href="https://www.benzinga.com/pressreleases/25/03/n44207026/doordash-tko-group-holdings-williams-sonoma-and-expand-energy-set-to-join-s-p-500-others-to-join-s">S&amp;P 500. </a>
What To Know: After the market close on Friday, S&amp;P Dow Jones Indices announced that DoorDash, TKO Group Holdings Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TKO#NYSE">TKO</a>), Williams-Sonoma Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WSM#NYSE">WSM</a>) and Expand Energy Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXE#NASDAQ">EXE</a>) will join the S&amp;P 500. The changes went into effect before the market open on Monday. 
DoorDash shares jumped as much as 7.5% on the news. The four companies will replace Borgwarner Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BWA#NYSE">BWA</a>), Teleflex Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>), Celanese Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CE#NYSE">CE</a>) and FMC Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMC#NYSE">FMC</a>) in the index. 
When companies are added to major indices, they often see an increase in share prices as index funds that track the S&amp;P 500 buy shares of the newly added companies in order to stay aligned with the overall index.
Check This Out: <a href="https://www.benzinga.com/markets/equities/25/03/44212796/palantir-joins-sp-100-after-ai-driven-rally-stock-surges-almost-60-since-trump-victory">Palantir Joins S&amp;P 100 After AI-Driven Rally, Stock Surges Almost 60% Since Trump Victory</a>
<h3 class="wp-block-heading">How To Buy DASH Stock</h3>
Besides going to a brokerage platform to purchase a share &#8211; or fractional share &#8211; of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument. 
For example, in DoorDash's case, it&#8217;s in the Consumer Discretionary sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
DASH Price Action: <a href="http://benzinga.com/quote/dash">DoorDash shares</a> were up 3.58% at $184.45 at the time of publication Monday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Movers

DASH

DoorDash Stock Is Rising Monday: What's Driving The Action?

Morgan Stanley analyst Patrick Wood maintains Teleflex (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) with a Overweight and lowers the price target from $275 to $191.

Morgan Stanley Maintains Overweight on Teleflex, Lowers Price Target to $191

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Citigroup analyst Patrick Donnelly downgraded Quest Diagnostics Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) from Buy to Neutral and maintained the price target of $185. Quest Diagnostics shares closed at $176.95 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>UBS analyst Manav Gupta downgraded the rating for Green Plains Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GPRE#NASDAQ">GPRE</a>) from Buy to Neutral and announced a $7 price target. Green Plains shares closed at $5.41 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst Joseph Stringer downgraded Pliant Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLRX#NASDAQ">PLRX</a>) from Buy to Hold and maintained the price target of $10. Pliant Therapeutics shares closed at $1.38 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>B of A Securities analyst Craig Bijou downgraded the rating for Teleflex Incorporated (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TFX#NYSE">TFX</a>) from Neutral to Underperform and lowered the price target from $235 to $140. Teleflex shares closed at $135.13 on Monday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Barclays analyst Ramsey El-Assal downgraded AvidXchange Holdings, Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AVDX#NASDAQ">AVDX</a>) from Overweight to Equal-Weight and lowered the price target from $13 to $8. AvidXchange shares closed at $7.42 on Monday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/price-target/25/03/44083539/wall-streets-most-accurate-analysts-give-their-take-on-3-defensive-stocks-delivering-high-dividend-yields-3">Wall Street&#8217;s Most Accurate Analysts Give Their Take On 3 Defensive Stocks Delivering High-Dividend Yields</a></li>
</ul>

Downgrades

Markets

AVDX

GPRE

PLRX

This Teleflex Analyst Turns Bearish; Here Are Top 5 Downgrades For Tuesday

Press Releases

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Teleflex Incorporated - TFX

Teleflex Announces Clinical and Real-World Evidence Studies and Physician Educational Opportunities to Be Highlighted at the 2025 American Urological Association (AUA) Annual Meeting

Legal

Rosen Law Firm Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation – TFX

Teleflex receives FDA 510(k) Clearance for Expanded Indications of the QuikClot Control+™ Hemostatic Device

Teleflex to Present at the BofA Securities 2025 Health Care Conference

TFX Investors Have Opportunity to Join Teleflex Incorporated Fraud Investigation with the Schall Law Firm

Teleflex Reports First Quarter Financial Results and Full Year 2025 Outlook

Teleflex Investor News: Rosen Law Firm Encourages Teleflex Incorporated Investors to Inquire About Securities Class Action Investigation - TFX

Teleflex Incorporated Announcement: If You Have Suffered Losses in Teleflex Incorporated (NYSE: TFX), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

Comments

Teleflex

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL